Identification of two early blood biomarkers ACHE and CLEC12A for improved risk stratification of critically ill COVID-19 patients.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 03 2023
16 03 2023
Historique:
received:
18
05
2022
accepted:
16
02
2023
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
22
3
2023
Statut:
epublish
Résumé
In order to identify biomarkers for earlier prediction of COVID-19 outcome, we collected blood samples from patients with fatal outcomes (non-survivors) and with positive clinical outcomes (survivors) at ICU admission and after seven days. COVID-19 survivors and non-survivors showed significantly different transcript levels for 93 genes in whole blood already at ICU admission as revealed by RNA-Seq. These differences became even more pronounced at day 7, resulting in 290 differentially expressed genes. Many identified genes play a role in the differentiation of hematopoietic cells. For validation, we designed an RT-qPCR assay for C-type lectin domain family 12 member A (CLEC12A) and acetylcholinesterase (ACHE), two transcripts that showed highest potential to discriminate between survivors and non-survivors at both time points. Using our combined RT-qPCR assay we examined 33 samples to accurately predict patient survival with an AUROC curve of 0.931 (95% CI = 0.814-1.000) already at ICU admission. CLEC12A and ACHE showed improved prediction of patient outcomes compared to standard clinical biomarkers including CRP and PCT in combination (AUROC = 0.403, 95% CI = 0.108-0.697) or SOFA score (AUROC = 0.701 95% CI = 0.451-0.951) at day 0. Therefore, analyzing CLEC12A and ACHE gene expression from blood may provide a promising approach for early risk stratification of severely ill COVID-19 patients.
Identifiants
pubmed: 36928077
doi: 10.1038/s41598-023-30158-1
pii: 10.1038/s41598-023-30158-1
pmc: PMC10019437
doi:
Substances chimiques
Acetylcholinesterase
EC 3.1.1.7
Biomarkers
0
CLEC12A protein, human
0
Lectins, C-Type
0
Receptors, Mitogen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4388Informations de copyright
© 2023. The Author(s).
Références
Arthritis Res Ther. 2013 Jul 09;15(4):R73
pubmed: 23837669
Genome Med. 2021 Jan 13;13(1):7
pubmed: 33441124
Med Klin Intensivmed Notfmed. 2020 Apr;115(3):175-177
pubmed: 32166350
BMC Anesthesiol. 2020 Nov 23;20(1):292
pubmed: 33225902
Front Genet. 2019 May 03;10:421
pubmed: 31130993
PLoS Comput Biol. 2009 Dec;5(12):e1000598
pubmed: 20011106
Bioinformatics. 2013 Nov 1;29(21):2790-1
pubmed: 23975764
Immunity. 2014 Mar 20;40(3):389-99
pubmed: 24631154
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
Exp Hematol. 2021 May;97:32-46.e35
pubmed: 33675821
BMJ Open. 2021 Jan 6;11(1):e044497
pubmed: 33408218
Nat Rev Genet. 2016 May;17(5):257-71
pubmed: 26996076
Crit Care. 2021 Jun 14;25(1):212
pubmed: 34127048
Arch Pathol Lab Med. 2020 Dec 1;144(12):1457-1464
pubmed: 32649222
Sci Rep. 2017 Mar 30;7:45477
pubmed: 28358118
Front Immunol. 2020 Feb 18;11:251
pubmed: 32133013
Sci Rep. 2020 Nov 25;10(1):20560
pubmed: 33239692
Theory Biosci. 2012 Dec;131(4):281-5
pubmed: 22872506
Int J Mol Sci. 2017 Aug 18;18(8):
pubmed: 28820494
Genome Biol. 2014;15(12):550
pubmed: 25516281
Front Pediatr. 2021 Mar 30;8:607647
pubmed: 33859967
Eur J Immunol. 2008 Apr;38(4):1157-63
pubmed: 18350551
Nucleic Acids Res. 2019 Jul 2;47(W1):W191-W198
pubmed: 31066453
Nat Rev Immunol. 2020 Sep;20(9):515-516
pubmed: 32728221
BMC Genomics. 2019 Jan 5;20(1):6
pubmed: 30611200
EMBO Mol Med. 2021 Nov 8;13(11):e13714
pubmed: 34661368
Sci Rep. 2021 Mar 29;11(1):7052
pubmed: 33782412
Cytokine. 2021 May;141:155428
pubmed: 33550165
Nat Immunol. 2021 Jan;22(1):32-40
pubmed: 33277638
Immunology. 2018 Feb;153(2):171-178
pubmed: 28921535
Cell Death Discov. 2020 Dec 8;6(1):141
pubmed: 33293514
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Res Med Sci. 2021 Nov 29;26:115
pubmed: 35126578
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
BMC Med Genomics. 2009 Aug 05;2:49
pubmed: 19656400
Crit Care Med. 2019 May;47(5):e394-e402
pubmed: 30720537
Proc Natl Acad Sci U S A. 2019 Sep 10;116(37):18544-18549
pubmed: 31451663
FEBS J. 2007 Aug;274(15):3799-845
pubmed: 17651090
Sci Immunol. 2022 Jan 07;7(67):eabm5505
pubmed: 34995097
Toxicol Rep. 2020 Apr 30;7:658-663
pubmed: 32355638
Immunity. 2021 Jun 8;54(6):1304-1319.e9
pubmed: 34048708
Sci Rep. 2021 Oct 19;11(1):20638
pubmed: 34667241
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Cell. 2022 Mar 3;185(5):916-938.e58
pubmed: 35216673
Genome Med. 2016 Jul 01;8(1):73
pubmed: 27368373
Eur J Immunol. 2006 Aug;36(8):2159-69
pubmed: 16838277
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Mayo Clin Proc. 2020 Jun;95(6):1138-1147
pubmed: 32376101